Penn Capital Management Company LLC Takes Position in Amneal Pharmaceuticals, Inc. $AMRX

Penn Capital Management Company LLC bought a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,001,951 shares of the company’s stock, valued at approximately $12,655,000.

A number of other hedge funds have also recently modified their holdings of the business. Jefferies Financial Group Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $907,000. Global Retirement Partners LLC bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $115,000. Covestor Ltd boosted its holdings in shares of Amneal Pharmaceuticals by 4,883.4% during the 4th quarter. Covestor Ltd now owns 9,618 shares of the company’s stock valued at $121,000 after buying an additional 9,425 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Amneal Pharmaceuticals by 38.2% during the 4th quarter. Handelsbanken Fonder AB now owns 53,900 shares of the company’s stock valued at $679,000 after buying an additional 14,900 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Amneal Pharmaceuticals by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 41,381 shares of the company’s stock valued at $521,000 after buying an additional 4,461 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $12.79 on Wednesday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $7.07 and a fifty-two week high of $15.42. The business has a 50-day simple moving average of $12.58 and a two-hundred day simple moving average of $12.90. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of 33.66 and a beta of 1.32.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million during the quarter. As a group, research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on AMRX. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Truist Financial boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, May 11th. Finally, UBS Group assumed coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.17.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.